Repatha Employer + ICHRA Coverage Navigation: How to Get Evolocumab Cheaper in 2026

Why Repatha Costs So Much Without Help

Evolocumab is a fully human monoclonal antibody that inhibits PCSK9, preventing the degradation of LDL receptors on hepatocytes. The result is dramatic LDL lowering. In the FOURIER trial (N=27,564), evolocumab reduced LDL-C by 59% from a median baseline of 92 mg/dL, reaching a median on-treatment LDL of 30 mg/dL at 48 weeks compared to 92 mg/dL in the placebo group [1]. That clinical performance comes at a biologics price point.

Amgen's wholesale acquisition cost for Repatha sits near $730 per month in 2026. The FDA approved the 140 mg/mL autoinjector pen and prefilled syringe formulations in August 2015 [2]. Because no biosimilar for evolocumab has reached broad U.S. Commercial distribution at meaningful scale as of early 2026, list prices have not faced the compression seen with other biologics.

Why Payers Push Back

Payers resist coverage because statins cost under $10 per month as generics. The American College of Cardiology / American Heart Association 2018 cholesterol guideline recommends maximizing statin therapy before adding a PCSK9 inhibitor, reserving PCSK9 inhibition for patients with ASCVD and LDL-C ≥70 mg/dL on maximally tolerated statins [3]. Employer plan formularies mirror this hierarchy. Expect step therapy requirements that document at least two high-intensity statins (typically rosuvastatin 40 mg and atorvastatin 40 to 80 mg) plus ezetimibe before a prior authorization will be approved.

What "Maximally Tolerated" Actually Means for PA

Statin intolerance is legitimate and documentable. The National Lipid Association defines statin intolerance as myalgia, myopathy, or other adverse effects that prevent ongoing use at any dose [4]. If a patient cannot tolerate any statin dose, that satisfies the step-therapy requirement for most PA forms. The prescriber must specify the statin tried, the dose, the duration, and the adverse effect. Generic documentation such as "patient prefers not to take statins" will fail PA.

How Employer Group Health Plans Cover Repatha

Most mid-size and large employer plans use pharmacy benefit managers, Express Scripts, CVS Caremark, and OptumRx are the three largest, who place Repatha on a specialty tier. Specialty tier cost-sharing typically runs 25 to 33% coinsurance or a flat $150, $400 monthly copay, depending on plan design.

Formulary Tiers and Step Therapy

PBMs negotiate net prices through rebates that do not reduce the patient's point-of-sale cost unless the plan uses copay accumulator programs. Under accumulator designs, Amgen's copay card payments do not count toward the plan deductible. Some states have passed accumulator prohibition laws, so the state of the employer plan's situs matters. Self-insured (ERISA) plans are exempt from state accumulator laws under federal preemption [5].

Before submitting a PA, confirm which tier Repatha sits on and whether an alternative PCSK9 inhibitor (alirocumab/Praluent) is preferred. Some PBMs grant preferred-tier status to alirocumab based on rebate agreements, lowering its PA bar. If clinical equivalence is acceptable, the path-of-least-resistance may be alirocumab first. Both drugs achieve similar LDL reductions in head-to-head PK modeling, though no powered MACE trial has directly compared the two agents [6].

The Prior Authorization Packet

A complete PA submission for employer group plans typically requires:

• Recent fasting lipid panel (within 90 days) showing LDL-C at or above plan threshold
• Documentation of at least two statin trials (drug, dose, duration, outcome)
• Diagnosis code: E78.00 (pure hypercholesterolemia) or I25.10 (atherosclerotic heart disease) or Z84.49 (FH family history), as appropriate
• ICD-10 for statin intolerance if applicable: M79.3 (myalgia)
• Prescriber NPI and DEA (required by some specialty pharmacies)

Turnaround is 3 to 7 business days for standard PA and 24 to 72 hours for urgent cases under CMS timelines, which also serve as the informal benchmark for commercial plans [7].

Specialty Pharmacy Dispensing

Repatha is almost universally dispensed through specialty pharmacies rather than retail. Amgen's preferred specialty pharmacy network includes CVS Specialty, Accredo, Walgreens Specialty, and AllianceRx. The specialty pharmacy handles benefits verification, PA resubmission support, and copay card enrollment simultaneously if the prescriber's office uses Amgen's CornerStone Support program [8].

ICHRA and Repatha: The Reimbursement Path

An Individual Coverage HRA (ICHRA) is an employer-funded account that reimburses employees for individual health insurance premiums and, depending on plan document design, qualified medical expenses under IRC Section 213(d). The IRS finalized ICHRA rules under Treasury Regulation 26 CFR Part 54 in June 2019, with plans permitted starting January 1, 2020 [9].

Does an ICHRA Reimburse Repatha Directly?

Prescription drugs are qualified medical expenses under IRC 213(d) [10]. If the ICHRA plan document explicitly includes 213(d) medical expenses (not just premiums), Repatha costs paid out-of-pocket are reimbursable. The employee submits receipts from the specialty pharmacy. The reimbursement is tax-free to the employee and deductible for the employer.

However, many employer ICHRA designs limit reimbursement to premiums only, particularly in small-business implementations, because premium-only designs reduce administrative burden. Employees should request a Summary Plan Description or plan document from HR and search for language referencing "Section 213(d) medical expenses" or "qualified medical expenses beyond premiums."

Stacking ICHRA with Individual Market Coverage

Under an ICHRA, the employee purchases an individual ACA marketplace plan. That marketplace plan has its own formulary. ACA plans must cover at least one drug per USP category, but PCSK9 inhibitors may sit on a non-preferred specialty tier with 40 to 50% coinsurance before out-of-pocket maximum. The employee can then use:

1. The individual plan's specialty benefit to reduce the allowed amount
2. Amgen's copay card (only valid if the individual plan qualifies as commercial, not a government plan)
3. ICHRA reimbursement for any remaining out-of-pocket above what the copay card covers

This three-layer stack is the most aggressive cost-reduction approach available to ICHRA participants. Actual net cost can reach near zero in years when the out-of-pocket maximum is met early and the copay card covers the gap [11].

ICHRA and HSA Compatibility

A standard ICHRA is not HSA-compatible unless the employee enrolls in an HSA-qualified High Deductible Health Plan (HDHP) through the individual market. If the ICHRA is "limited" to dental/vision only, HSA eligibility is preserved. The IRS issued guidance on this interaction in Notice 2019-45 [12]. Employees who want both ICHRA reimbursement and HSA contributions must confirm their individual marketplace plan meets HDHP criteria (2026 minimum deductible: $1,650 individual / $3,300 family per IRS Rev. Proc. 2025-19).

Amgen's Copay Card and Patient Assistance Programs

Repatha SupportPlus Copay Card

Amgen operates the Repatha SupportPlus program. Eligible commercially insured patients pay as little as $0 per month, with Amgen covering up to $3,600 per calendar year. Eligibility requires:

• Commercial insurance (not Medicare, Medicaid, CHIP, VA, or TRICARE)
• U.S. Residency
• Enrollment at amgensupportplus.com or via the specialty pharmacy at point of dispensing

The copay card is a credit-card-style card or an electronic benefit applied directly by the specialty pharmacy. Patients do not need to submit paper claims. The card renews each January 1 and must be re-enrolled annually.

Under accumulator adjudication (common in self-insured ERISA employer plans), the copay card payments do not count toward the deductible or out-of-pocket maximum. The patient's true financial exposure can therefore be deferred until the copay card's $3,600 annual limit is exhausted. If monthly cost-sharing is $300 per fill, the card covers 12 fills exactly. Plan design matters: in a year where the deductible is $4,000, an accumulator plan leaves the patient responsible for the full deductible even after the card runs out [13].

Amgen Safety Net Foundation

Patients without insurance, or whose household income is at or below 500% of the Federal Poverty Level, may qualify for free drug through the Amgen Safety Net Foundation. Applications are processed at amgensafetynetfoundation.com. The foundation program requires annual income documentation and a prescription from a licensed U.S. Prescriber. Processing typically takes 2 to 3 weeks after complete documentation is received.

340B Program Eligibility

Patients receiving care at a 340B-covered entity (federally qualified health centers, certain hospital outpatient departments, and Ryan White HIV/AIDS clinics) may access Repatha at the 340B ceiling price, which can be substantially below WAC. The 340B program is administered under Section 340B of the Public Health Service Act [14]. Not all 340B entities carry Repatha in their contract pharmacy network; the patient or prescriber must confirm availability at the specific dispensing site.

Step-by-Step: Getting Repatha Approved and Cheap

The following framework is designed for patients navigating employer or ICHRA coverage in 2026. Each step reflects current PA norms and Amgen program terms.

Step 1. Confirm your insurance type. Commercial employer group plan vs. ICHRA-funded individual plan vs. Medicare/Medicaid. This determines copay card eligibility and PA pathway.

Step 2. Obtain a qualifying lipid panel. LDL-C must be measured fasting within 90 days. Target value for PA eligibility is typically LDL-C ≥70 mg/dL (very high risk, ASCVD) or ≥100 mg/dL (high risk, FH without ASCVD) per ACC/AHA 2018 guidelines [3].

Step 3. Document statin history. The prescriber should generate a medication history note listing each statin, the maximum dose tried, the duration, and the reason for discontinuation or inadequate response. Two statins at high-intensity doses plus ezetimibe 10 mg is the standard bar.

Step 4. Submit the PA through the specialty pharmacy. Routing through Amgen's preferred specialty pharmacies (Accredo, CVS Specialty) provides PA support staff who know the plan-specific PA forms. Response time: 3 to 7 business days standard [7].

Step 5. Enroll in the copay card on the same day the PA is approved. Do this before the first fill. The specialty pharmacy can enroll the patient electronically during the benefit-verification call.

Step 6. If denied, file a peer-to-peer review request within 72 hours. The prescriber speaks directly with the PBM's reviewing physician. Approval rates after peer-to-peer are meaningfully higher than initial denials [15]. Prepare cardiovascular risk documentation: 10-year ASCVD risk score (PCE calculator), prior cardiac events, family history of premature ASCVD.

Step 7. If peer-to-peer fails, escalate to external independent review. Federal law (ACA Section 2719) mandates external independent review for adverse benefit determinations in non-grandfathered group health plans [16]. This review is binding on the plan. Typical turnaround: 45 to 60 days standard, 72 hours urgent.

Step 8. For ICHRA participants, submit ICHRA reimbursement claim. Attach specialty pharmacy receipt showing patient-paid amount after copay card application. Submit through the ICHRA administrator's portal (e.g., HRA Simple, Take Command Health, PeopleKeep, or employer's TPA).

Clinical Evidence Supporting Repatha Use

The access burden is justified by the clinical evidence. FOURIER (N=27,564) enrolled patients with established ASCVD and LDL-C ≥70 mg/dL on optimized statin therapy. Over a median follow-up of 2.2 years, evolocumab reduced the primary composite endpoint (cardiovascular death, MI, stroke, coronary revascularization, hospitalization for unstable angina) by 15% relative risk reduction (HR 0.85, 95% CI 0.79 to 0.92, P<0.001) [1]. The secondary endpoint of cardiovascular death, MI, or stroke was reduced by 20% (HR 0.80, 95% CI 0.73 to 0.88, P<0.001) [1].

LDL Reduction Magnitude

Mean LDL-C dropped from 92 mg/dL at baseline to 30 mg/dL at 48 weeks in the evolocumab arm of FOURIER. This degree of lowering is not achievable with any currently available oral agent. Rosuvastatin 40 mg reduces LDL by approximately 50 to 55%; ezetimibe adds another 15 to 20% reduction. Even at maximum oral therapy, residual LDL above 70 mg/dL is common in familial hypercholesterolemia [4].

Familial Hypercholesterolemia Data

In TESLA Part B (N=49), evolocumab 420 mg monthly reduced LDL-C by 30.9% in patients with homozygous FH, who are typically resistant to statins due to absent or dysfunctional LDL receptors [17]. The FDA's approval for HoFH was based in part on this trial [2]. HoFH patients have an estimated prevalence of 1 in 300,000 and face cardiovascular events in their teens and twenties without aggressive lipid lowering [18].

Safety Profile Relevant to Payer Negotiations

The ACC/AHA 2018 guideline notes that PCSK9 inhibitors have a favorable safety profile across trials, with no significant increase in myopathy, hepatotoxicity, or new-onset diabetes, unlike statins at high doses [3]. This point is useful in peer-to-peer reviews when a payer's medical director raises general biologics-safety concerns. Dr. Scott Grundy, lead author of the 2018 ACC/AHA guideline, stated in the guideline text: "PCSK9 inhibitors have emerged as the most potent LDL-C-lowering therapy available" [3].

Can You Use an HSA or FSA for Repatha?

Yes. Repatha is a prescription drug and qualifies as a medical expense under IRC Section 213(d). HSA and FSA funds can be used to pay for Repatha at the specialty pharmacy. This applies to:

• The patient-paid portion after insurance adjudication
• Any amount not covered by the copay card
• Out-of-pocket costs incurred before deductible satisfaction

The IRS confirms in Publication 502 that prescription medications are deductible medical expenses [10]. Using HSA dollars for Repatha is tax-advantaged: contributions reduce taxable income, earnings grow tax-free, and withdrawals for qualified medical expenses are tax-free. The 2026 HSA contribution limit is $4,300 (self-only) or $8,550 (family) per IRS Rev. Proc. 2025-19.

FSA funds are use-it-or-lose-it by plan year (with optional 2.5-month grace period or $660 rollover, per IRS Notice 2013-71 [19]), so timing Repatha fills to use available FSA balances before year-end is a practical cost tactic.

Medicare and Medicaid Patients: What This Article Does Not Cover

The Amgen SupportPlus copay card and ICHRA reimbursement strategies described above apply to commercially insured patients only. Medicare Part D covers Repatha through formulary tiers that vary by plan; the Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D took effect January 1, 2025 [20], which substantially reduces the financial burden for Medicare beneficiaries. Medicaid coverage of Repatha varies by state and is managed through state preferred drug lists and supplemental rebate agreements.